US/UK/Canada

Share

Pick a time period -

Nanoform sets two new near-term business targets for 2022

Insider information Nanoform Finland Plc January 3, 2022 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform sets two new near-term business targets for 2022 Helsinki, Finland – Nanoform, an innovative nanoparticle medicine enabling company, today announced two new near-term business targets for 2022. Nanoform’s near-term business targets are as follows, where the two first ones are new, while the two latter ones are re-iterated: · At least 20 new customer non-GMP[1] projects in 2022 (+67% vs 2021 target) · At least 3 new customer GMP projects in 2022 (+200% vs

Nanoform financial calendar for 2022

Company Announcement Nanoform Finland Plc December 10, 2021 04.45 p.m. Finnish time / 03.45 p.m. Swedish time Nanoform financial calendar for 2022 Helsinki, Finland – In this company announcement Nanoform provides its financial calendar for 2022, which include the planned publication dates of its financial reports, Annual Report and Annual General Meeting. Planned publication dates for Nanoform's financial reports in 2022: · report for Q4 2021 and full year 2021: 22 February 2022 · report for Q1 2022: 24 May 2022 · report for Q2 2022 and half-year 2022: 25

Nanoform Interim Report January – September 2021

Company Announcement Nanoform Finland Plc November 25, 2021 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform Interim Report January – September 2021 The strong momentum continues: all near-term business targets for 2021 achieved, rapid customer project intake accelerating, commercial team in Europe expanded, more line capacity added, ISMS certificate received, and a new near-term business target introduced: “Biologics pilot line for GMP in 2022”. 7-9/2021 key financials: - Revenue came in at EUR 0.48 million, up 198 % compared with EUR 0.16 million in 7-9/2020.

Resolutions of Nanoform Finland Plc's Extraordinary General Meeting on November 17, 2021

Company release Nanoform Finland Plc November 17, 2021 03:00 p.m. Finnish time / 02:00 p.m. Swedish time Resolutions of Nanoform Finland Plc's Extraordinary General Meeting on November 17, 2021 The Board of Directors Nanoform Finland Plc’s Extraordinary General Meeting, held on November 17, 2021, resolved that the Board of Directors consists of four members. Jeanne Thoma was elected as a new member of the Board of Directors (the “New Board Member”). Miguel Calado (chairperson), Albert Hæggström (ordinary member) and Mads Laustsen (ordinary member) continue as members of

Nanoform wins Star of Innovation award at the European Small and Mid-Cap Awards 2021

Press release Nanoform Finland Plc November 17, 2021 10:15 a.m. Finnish time / 09:15 a.m. Swedish time Nanoform wins Star of Innovation award at the European Small and Mid-Cap Awards 2021 Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, has won the Star of Innovation award at the 9[th] annual European Small and Mid-Cap Awards. The award win recognizes Nanoform as a listed company that places innovation at the center of its strategy for business development and introduces an innovative technology to the market. On the

Nanoform signs GMP agreement and achieves near-term business target

Insider information Nanoform Finland Plc November 15, 2021 05:05 p.m. Finnish time / 04:05 p.m. Swedish time Nanoform signs GMP agreement and achieves near-term business target Helsinki, Finland - Nanoform, an innovative nanoparticle medicine enabling company, today announced it has signed an agreement to manufacture GMP (Good Manufacturing Practice) nanoformed material for a European headquartered international company. This follows the Letter of Intent (LOI), signed between the parties in June 2021, to nanoform and develop, manufacture, and commercialize an improved version

Nanoform receives ISO/IEC 27001:2013 certification for its Information Security Management System

Press release Nanoform Finland Plc November 12, 2021 11:00 a.m. Finnish time / 10:00 a.m. Swedish time Nanoform receives ISO/IEC 27001:2013 certification for its Information Security Management System Helsinki, Finland - Nanoform, an innovative nanoparticle medicine enabling company, today announced it has received ISO/IEC 27001:2013 certification for its Information Security Management System (ISMS). The ISMS applies to all information, systems, processes, and people that operate, store, handle, and process Nanoform’s and its clients’ trusted data. It covers the IT services

Invitation to presentation of Nanoform’s Q3/2021 report on November 25, 2021

Press release Nanoform Finland Plc November 11, 2021 11:00 a.m. Finnish time / 10:00 a.m. Swedish time Invitation to presentation of Nanoform’s Q3/2021 report on November 25, 2021 Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, will publish its Q3/2021 report on November 25, 2021, at 8.10 a.m. Finnish time / 7.10 a.m. Swedish time. The company will hold a conference call and an online presentation on the same day at 3.00 p.m. Finnish time / 2.00 p.m. Swedish time. Nanoform will be represented by CEO Edward

Nanoform convenes EGM to elect Jeanne Thoma as board member

Company Announcement Nanoform Finland Plc October 18, 2021 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform convenes EGM to elect Jeanne Thoma as board member Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, will convene an extraordinary general meeting (EGM) on November 17, 2021, at 14:00 EEST to elect Jeanne Thoma as a new board member. The notice to the EGM was published simultaneously with this company announcement. Jeanne Thoma, a renowned global executive in the pharma industry, spent the first

Notice to the Extraordinary General Meeting of NANOFORM FINLAND PLC

Company Announcement Nanoform Finland Plc October 18, 2021 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Notice to the extraordinary General Meeting of NANOFORM FINLAND PLC The shareholders of Nanoform Finland Plc (business ID: 2730572-8) are hereby invited to the Extraordinary General Meeting to be held on 17 November 2021 at 14:00 (EET) at Viikinkaari 4, 00790 Helsinki, Finland (Cultivator II, meeting room 105, 1[st] floor). A. Agenda of the Meeting The following matters will be considered at the Extraordinary General Meeting: 1. Opening of the meeting 2.

Nanoform receives funding to solve challenges for global health

Press release Nanoform Finland Plc September 29, 2021 03:45 p.m. Finnish time / 02:45 p.m. Swedish time Nanoform receives funding to solve challenges for global health Helsinki, Finland – Nanoform, an innovative nanoparticle medicine enabling company, announces that Proof of Concept studies will be funded by the Bill & Melinda Gates Foundation to assess the added value Nanoform’s award-winning CESS[®] nanoparticle engineering technology can deliver to several of its drug development projects. Nanoform is working to develop nanomedicines with the ultimate aim of solving

Nanoform Finland Plc – Manager’s transactions – Gonçalo Andrade

Company release Nanoform Finland Plc Sep 24[th], 2021 05.30 p.m. Finnish time / 04.30 p.m. Swedish time Nanoform Finland Plc – Manager’s transactions – Gonçalo Andrade Manager’s transaction related to Nanoform Finland Plc’s other senior manager Gonçalo Andrade’s disposal of shares. ____________________________________________ Person subject to the notification requirement Name: Gonçalo Andrade Position: Other senior manager Issuer: Nanoform Finland Plc LEI: 743700JJO2NU8LBS1592 Notification type: INITIAL NOTIFICATION Reference number:

Nanoform shortlisted for the European Small and Mid-Cap Awards 2021

Press release Nanoform Finland Plc September 23, 2021 14:30 a.m. Finnish time / 13.30 a.m. Swedish time Nanoform shortlisted for the European Small and Mid-Cap Awards 2021 Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, has made the shortlist in the ‘Star of Innovation’ category of the 9[th] annual European Small and Mid-Cap Awards. The nomination is based on Nanoform being a listed company that places innovation at the centre of its strategy for business development by introducing innovative technology to the

Nanoform technology delivers successful results for Herantis CDNF drug candidate

Press release Nanoform Finland Plc September 9, 2021 08:00 a.m. Finnish time / 07:00 a.m. Swedish time Nanoform technology delivers successful results for Herantis CDNF drug candidate Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, and Herantis Pharma Plc (“Herantis”), focusing on disease modifying therapies for debilitating neurodegenerative diseases based on the natural body protein CDNF (Cerebral Dopamine Neurotrophic Factor), today announced that results from the Nanoform Proof of Concept (PoC) project show that

The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees

Company release Nanoform Finland Plc August 27, 2021 04:30 p.m. Finnish time / 03:30 p.m. Swedish time The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees Helsinki, Finland – The Annual General Meeting of Nanoform Finland Plc (“Nanoform”) has on 6 April 2021 authorized the company’s Board of Directors to decide on the issuance of shares as well as the issuance of special rights entitling to shares referred to in Chapter 10 Section 1 of the Finnish Limited Liability Companies Act by one or several decisions. The Board of

Nanoform Interim Report January – June 2021

Company Announcement Nanoform Finland Plc August 26, 2021 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform Interim Report January – June 2021 The strong momentum continues: Additional line capacity, more projects, new clients, the number of employees crosses 100, while the gross margin forcefully breaks through 90 per cent. Letter of intent signed for the development, manufacturing, and commercialization of a by nanoforming improved version of a current blockbuster drug. Q2/2021 key financials: - Revenue came in at EUR 0.55 million, up 185% compared with EUR 0.

Invitation to presentation of Nanoform’s Q2/2021 report on August 26, 2021

Press release Nanoform Finland Plc August 12, 2021 11:00 a.m. Finnish time / 10:00 a.m. Swedish time Invitation to presentation of Nanoform’s Q2/2021 report on August 26, 2021 Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, will publish its Q2/2021 report on August 26, 2021, at 8.10 a.m. Finnish time / 7.10 a.m. Swedish time. The company will hold a conference call and an online presentation on the same day at 3.00 p.m. Finnish time / 2.00 p.m. Swedish time. Nanoform will be represented by CEO Edward Hæggström,

Nanoform and Boehringer Ingelheim execute master services agreement

Press release Nanoform Finland Plc August 3, 2021 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform and Boehringer Ingelheim execute master services agreement Helsinki, Finland – Nanoform, an innovative nanoparticle medicine enabling company, announces that Proof of Concept studies may now be performed for Boehringer Ingelheim to assess the added value Nanoform’s award-winning CESS[®] technology can deliver to its drug development projects. The two parties have executed a master services agreement (MSA) to initiate projects in the pre-clinical early development

Nanoform Finland Plc – Manager’s transactions – Gonçalo Andrade

Company release Nanoform Finland Plc June 14, 2021 03:00 p.m. Finnish time / 02:00 p.m. Swedish time Nanoform Finland Plc – Manager’s transactions – Gonçalo Andrade Helsinki, Finland – Manager’s transaction related to Nanoform Finland Plc’s other senior manager Gonçalo Andrade’s share subscription with stock options from option program 2/2019. ____________________________________________ Person subject to the notification requirement Name: Gonçalo Andrade Position: Other senior manager Issuer: Nanoform Finland Plc LEI: 743700JJO2NU8LBS1592 Notification

The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees

Company release Nanoform Finland Plc June 11, 2021 06:15 p.m. Finnish time / 05:15 p.m. Swedish time The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees Helsinki, Finland – The Annual General Meeting of Nanoform Finland Plc (“Nanoform”) has on 6 April 2021 authorized the company’s Board of Directors to decide on the issuance of shares as well as the issuance of special rights entitling to shares referred to in Chapter 10 Section 1 of the Finnish Limited Liability Companies Act by one or several decisions. The Board of Directors

Share subscriptions based on Nanoform Finland Plc’s multiple Stock Option Programs

Company release Nanoform Finland Plc June 11, 2021 06:15 p.m. Finnish time / 05:15 p.m. Swedish time Share subscriptions based on Nanoform Finland Plc’s multiple Stock Option Programs Helsinki, Finland – Between June 4 and June 7, 2021, a total of 168,700 Nanoform Finland Plc’s (the “Company” or “Nanoform“) new shares have been subscribed for with the Company’s 2/2019, 3/2019, 5/2019 and 1/2020 stock options programs. The entire subscription price for subscriptions made with the stock options of EUR 187,505 will be entered in the Company’s reserve for invested unrestricted

Nanoform raises its mid-term business targets for 2025

Insider information Nanoform Finland Plc June 2, 2021 04:00 p.m. Finnish time / 03:00 p.m. Swedish time Nanoform raises its mid-term business targets for 2025 Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, today announced its raised mid-term business targets for 2025. The new targets are as follows: · To nanoform annually at least 70 new active pharmaceutical ingredients, or ‘APIs’ (40% increase from the previous target of at least 50 new APIs annually) · To have in place 35 operating production lines, of

Nanoform Interim Report January – March (Q1) 2021

Company Announcement Nanoform Finland Plc May 27, 2021 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform Interim Report January – March (Q1) 2021 Strong momentum continues: three new non-GMP lines commissioned, four new clients signed, and six new customer PoC projects commenced. In addition, positive results from first clinical study announced, two near-term business targets achieved (“First Biologics PoC in 2021” and “at least three new non-GMP lines in 2021”), next generation STARMAP[®] launched, EUR 40 million successfully raised and commercial teams in the US

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media